See the DrugPatentWatch profile for Ibsrela
The cost of Ibsrela 50 mg can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. Specific pricing details are not publicly available and are typically determined by individual pharmacies and the patient's prescription drug plan.
How can I find out the exact cost of Ibsrela 50 mg?
To determine the precise cost of Ibsrela 50 mg, it is recommended to contact your local pharmacy. You can also inquire with your health insurance provider about coverage for this medication and any associated co-pays or deductibles. Pharmaceutical manufacturers often provide patient assistance programs that may help reduce out-of-pocket expenses for eligible individuals.
What is Ibsrela used for?
Ibsrela (tenapanor) is a medication prescribed to treat irritable bowel syndrome with constipation (IBS-C) in adults [1]. It works by reducing the absorption of both phosphate and calcium in the gastrointestinal tract [2].
How does Ibsrela work?
Ibsrela is a novel, first-in-class, non-absorbed, oral, dual NHE3 and calcium H+-K+ ATPase inhibitor [1][2]. By inhibiting sodium-hydrogen exchanger 3 (NHE3) in the small intestine and colon, it reduces intestinal absorption of sodium and, consequently, water, which can help alleviate constipation associated with IBS-C [2].
What are the potential side effects of Ibsrela?
Common side effects of Ibsrela may include diarrhea, nausea, vomiting, abdominal distension, and flatulence [1]. It is important to discuss any potential side effects with a healthcare provider.
Does Ibsrela have patent protection?
Information regarding the specific patent status and expiry dates for Ibsrela is available through specialized patent databases [3]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be a resource for understanding market exclusivity [3].
Who manufactures Ibsrela?
Ibsrela is manufactured by Ardelyx, Inc. [1].
How does Ibsrela compare to other IBS-C treatments?
Ibsrela offers a different mechanism of action compared to other treatments for IBS-C. While some medications focus on increasing stool water content or affecting gut motility, Ibsrela targets the absorption of sodium and water in the intestines [2]. Patients and healthcare providers consider these differences when choosing the most appropriate treatment plan.
Sources:
[1] https://www.ardelyx.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430988/
[3] https://drugpatentwatch.com/